Miles DW: Update on herceptin in the clinical setting. Breast Cancer Res. 2001.
Google Scholar
Scanlan MJ, Jager D: Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. 2001, 3: 95-98. 10.1186/bcr278.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 2000, 6: 322-326.
Google Scholar
Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature. 2001, 411: 380-384. 10.1038/35077246.
Article
CAS
PubMed
Google Scholar
Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthove R, Cerottini JC, Boon T, Gairin JE, Van den Eynde BJ: Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity. 2000, 12: 107-117.
Article
CAS
PubMed
Google Scholar
Zaks TZ, Rosenberg SA: Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cyto-toxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998, 58: 4902-4908.
CAS
PubMed
Google Scholar
Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogen recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995, 181: 2109-2117.
Article
CAS
PubMed
Google Scholar
Kobayashi H, Wood M, Song Y, Apella E, Celis E: Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 2000, 60: 5228-5236.
CAS
PubMed
Google Scholar
Gilboa E: The makings of a tumor rejection antigen. Immunity. 1999, 11: 263-270.
Article
CAS
PubMed
Google Scholar
Zeh HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC: High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999, 162: 989-994.
CAS
PubMed
Google Scholar
Viner NJ, Nelson CA, Deck B, Unanue ER: Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J Immunol. 1996, 156: 2365-2368.
CAS
PubMed
Google Scholar
Murray JL, Przepiorka D, Ioannides C: Clinical trials of HER-2/neu-specific vaccines. Semin Oncol. 2000, 27(suppl 11): 71-75.
CAS
PubMed
Google Scholar
Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000, 96: 3102-3108.
CAS
PubMed
Google Scholar
Disis ML, Grabstein KH, Sleath PR, Cheever MA: Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999, 5: 1289-1297.
CAS
PubMed
Google Scholar
Knutson KL, Schiffman K, Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity. J Clin Invest. 2001, 107: 477-484.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola F, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers-Freezer L, White D: Impact of cytokine administration on the generation of anti-tumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol. 1999, 163: 1690-1695.
CAS
PubMed
PubMed Central
Google Scholar
Marchant M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier M, Rankin E, Parmiani G, Arienti F, Humblet Y, Boulond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van den Bruggen P, Boon T: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999, 80: 219-230. 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.3.CO;2-J.
Google Scholar
Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today. 1997, 18: 89-95. 10.1016/S0167-5699(96)10075-X.
Article
CAS
PubMed
Google Scholar
Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesato K, Apella E, Sette A, Celis E: The multiepitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998, 59: 1-14. 10.1016/S0198-8859(97)00255-3.
Article
CAS
PubMed
Google Scholar
Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Apella E, Sekikawa T, Matsumoto Y, Kiessling R: Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer. 1998, 78: 202-208. 10.1002/(SICI)1097-0215(19981005)78:2<202::AID-IJC14>3.3.CO;2-R.
Article
CAS
PubMed
Google Scholar
Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA: Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum Immunol. 1997, 52: 109-118. 10.1016/S0198-8859(96)00292-3.
Article
CAS
PubMed
Google Scholar
Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Apella E, Sette A, Celis E, Kiessling R: Identification of new HER2/ neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinoma and melanomas. J Immunol. 1999, 163: 1037-1044.
CAS
PubMed
Google Scholar
Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, Dimaio JM, Lyerly HK, Gazdar AF, Eberlein TJ: HER-2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 1994, 54: 3387-3390.
CAS
PubMed
Google Scholar
Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E: Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 1999, 59: 431-435.
CAS
PubMed
Google Scholar
Tanaka H, Tsunoda T, Nukaya I, Sette A, Matsuda K, Umano Y, Yamaue H, Takesato K, Tanimura H: Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br J Cancer. 2001, 84: 94-96. 10.1054/bjoc.2000.1547.
Article
CAS
PubMed
PubMed Central
Google Scholar
Okugawa T, Ikuta Y, Takahashu Y, Obata H, Tanida K, Watanabe M, Imai S, Furugen R, Nagata Y, Toyoda N, Shiku H: A novel human HER2-derived peptide homologous to the mouse Kd-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur J Immunol. 2000, 30: 3338-3346. 10.1002/1521-4141(200011)30:11<3338::AID-IMMU3338>3.3.CO;2-V.
Article
CAS
PubMed
Google Scholar
Ikuta Y, Okugawa T, Furugen R, Nagata Y, Takahashi Y, Wang L, Ikeda H, Watanabe M, Imai S, Shiku H: A HER2/neu derived peptide, a Kd-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8+ cytotoxic T lymphocytes. Int J Cancer. 2000, 87: 553-558. 10.1002/1097-0215(20000815)87:4<553::AID-IJC15>3.0.CO;2-8.
Article
CAS
PubMed
Google Scholar